

an immediate release layer of carbidopa-levodopa.

12. A method as claimed in Claim 1, the oral dosage formulation comprising a multilayer tablet wherein at least one sustained release layer of carbidopa-levodopa is separated from at least one immediate release layer of carbidopa-levodopa by an excipient layer which may be drug-free and does not necessarily contain rate-controlling polymers.

13. The pharmaceutical composition of Claim 5 wherein the oral dosage form comprises a bilayer tablet or pellet, the latter to be administered in a capsule dosage form and comprises a sustained release core layer of carbidopa-levodopa overcoated by an immediate release layer of carbidopa-levodopa.

14. The pharmaceutical composition of Claim 5 wherein the oral dosage form comprises a multilayer tablet including at least one layer of sustained release carbidopa-levodopa separated from at least one layer of immediate release carbidopa-levodopa by an excipient layer which may be drug-free and does not necessarily contain rate-controlling polymers.

15. The pharmaceutical composition of Claim 8 wherein the oral dosage form comprises a bilayer tablet or pellet, the latter to be administered in a capsule dosage form and comprises a sustained release core layer of carbidopa-levodopa overcoated by an immediate release layer of carbidopa-levodopa.

16. The pharmaceutical composition of Claim 8 wherein the oral dosage form comprises a multilayer tablet including at least one layer of sustained release